StockData
VolitionRx Ltd logo

VolitionRx Ltd (VNRX) income statement

VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.18−0.01 (-3.02%)

Close on Nov 18, 2026Market cap $2.50MP/E –Yield –

VolitionRx Ltd income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-790.2%
Net margin
-1043.1%
Return on equity, FY2025
79.0%

Financial strength

Current ratio
0.30
Debt to equity
-0.22
Debt to assets
85.0%
Cash to current liabilities
20.8%

Valuation

P/E ratio
–
Price to sales
1.02
Price to book
–
Dividend yield
–

See a number that looks wrong?